Biogen Investors Are Losing Patience

Biotech giant Biogen needs to quickly rebuild its new drug pipeline, a risky and expensive undertaking, to win investors back.

from WSJ.com: Markets https://ift.tt/2qZX3TB
via https://ifttt.com/ IFTTT